Laboratorios Farmaceuticos ROVI SA
OTC:LABFF
Intrinsic Value
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. [ Read More ]
The intrinsic value of one
LABFF
stock under the Base Case scenario is
80.72
USD.
Compared to the current market price of 86.05 USD,
Laboratorios Farmaceuticos ROVI SA
is
Overvalued by 6%.
Laboratorios Farmaceuticos ROVI SA's market capitalization is 4.1B EUR.
LABFF stock price is 86.05 USD.
LABFF stock (80.72 USD) is 6% less than its price (86.05 USD).
LABFF stock (72.65 USD) is 16% less than its price (86.05 USD). Open Relative Valuation
LABFF.
LABFF's Revenue has grown by 1% over the past 12 months.
LABFF has positive Net Debt. This means that the company has more debt (52m EUR) than cash and short-term investments (25m EUR).
LABFF's Revenue is forecast to grow at a rate of 8% per year over the next 3 years.
LABFF's ROE (Return on Equity) has increased in the last 3 years from 26% to 32%.
LABFF has positive Net Income for the last twelve months.
LABFF's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 26%.
LABFF's ROE (Return on Equity) for the past 12 months is very high and is equal to 32%.
LABFF has positive Operating Income for the last twelve months.
LABFF has positive Free Cash Flow for the last twelve months.
LABFF's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 57% to 26%.
LABFF's Revenue has been growing by an exceptional 25% per year for the last 3 years.
LABFF's short-term assets (509m EUR) exceed its short-term liabilties (200m EUR).
LABFF has positive Gross Profit for the last twelve months.
LABFF's long-term assets (800m EUR) exceed its long-term liabilties (260m EUR).
LABFF has very high three-year average ROE (Return on Equity): 45%. The company is very efficient at transforming stockholders' equity into net income.
LABFF's D/E (Debt to Equity) is very low and is equal to 0.1.
LABFF has very high three-year average ROIC (Return on Invested Capital): 49%. The company is very efficient at using invested capital to generate operating income.
LABFF's Altman Z-Score is very high and is equal to 10.53.
LABFF earns more than enough operating income (220m EUR) to safely cover interest payments on its debt (388k EUR).
Valuation Backtest
Laboratorios Farmaceuticos ROVI SA
Run backtest to discover the historical profit from buying and selling
LABFF
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Laboratorios Farmaceuticos ROVI SA
Balance Sheet Decomposition
Laboratorios Farmaceuticos ROVI SA
| Current Assets | 509.3m |
| Cash & Short-Term Investments | 25.3m |
| Receivables | 143.3m |
| Other Current Assets | 340.7m |
| Non-Current Assets | 290.6m |
| Long-Term Investments | 591k |
| PP&E | 253.7m |
| Intangibles | 33.9m |
| Other Non-Current Assets | 2.4m |
| Current Liabilities | 199.8m |
| Accounts Payable | 107.6m |
| Accrued Liabilities | 7.6m |
| Other Current Liabilities | 84.7m |
| Non-Current Liabilities | 60.7m |
| Long-Term Debt | 52.2m |
| Other Non-Current Liabilities | 8.4m |
Earnings Waterfall
Laboratorios Farmaceuticos ROVI SA
|
Revenue
|
829.5m
EUR
|
|
Cost of Revenue
|
-337.2m
EUR
|
|
Gross Profit
|
492.3m
EUR
|
|
Operating Expenses
|
-272m
EUR
|
|
Operating Income
|
220.3m
EUR
|
|
Other Expenses
|
-49.9m
EUR
|
|
Net Income
|
170.3m
EUR
|
Free Cash Flow Analysis
Laboratorios Farmaceuticos ROVI SA
LABFF Profitability Score
Profitability Due Diligence
Laboratorios Farmaceuticos ROVI SA's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
Score
Laboratorios Farmaceuticos ROVI SA's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
LABFF Solvency Score
Solvency Due Diligence
Laboratorios Farmaceuticos ROVI SA's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Score
Laboratorios Farmaceuticos ROVI SA's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LABFF Price Targets Summary
Laboratorios Farmaceuticos ROVI SA
According to Wall Street analysts, the average 1-year price target for
LABFF
is 82.27 USD
with a low forecast of 72.06 USD and a high forecast of 105.56 USD.
Shareholder Return
ROVI Price
Laboratorios Farmaceuticos ROVI SA
| Average Annual Return | 31.95% |
| Standard Deviation of Annual Returns | 57.97% |
| Max Drawdown | -6% |
| Market Capitalization | 4.1B EUR |
| Shares Outstanding | 53 369 752 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Laboratorios Farmaceuticos ROVI SA
Country
Industry
Market Cap
Dividend Yield
Description
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. The company is headquartered in Madrid, Madrid and currently employs 1,751 full-time employees. The company went IPO on 2007-10-26. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The firm owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
LABFF
stock under the Base Case scenario is
80.72
USD.
Compared to the current market price of 86.05 USD,
Laboratorios Farmaceuticos ROVI SA
is
Overvalued by 6%.
You don't have any saved screeners yet
